Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03890003 · ClinicalTrials.gov registry record · NA
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes
A NA study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT03890003: Completed NA study, sponsored by Eli Lilly and Company.
NCT03890003 is a NA study that has completed, run by Eli Lilly and Company. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03890003, a NA study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this early feasibility study is to assess the predictive low glucose suspend (PLGS) feature's safety, functionality and performance.
Primary Outcome
Number of AEs
Interventions
- DEVICE AID System
- DRUG Insulin Lispro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-03-28 |
| Est. Completion | 2019-05-06 |
| Phase | NA |
What the finished NCT03890003 record still lists
NCT03890003 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which AID System is the first listed.
NCT03890003 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03890003 about?
NCT03890003 is a clinical study titled "A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes". The purpose of this early feasibility study is to assess the predictive low glucose suspend (PLGS) feature's safety, functionality and performance.
What is the current status of trial NCT03890003?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2019-03-28. Estimated completion is 2019-05-06.
What interventions are being tested in trial NCT03890003?
The interventions under investigation include: AID System (DEVICE), Insulin Lispro (DRUG).
Who is sponsoring clinical trial NCT03890003?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03890003's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI